Evotec/Oxford Asymmetry To Exchange Technology For Equity Investments
Executive Summary
The Evotec/Oxford Asymmetry merged company will look to license technology in exchange for equity investments in new ventures, Evotec CEO Karsten Henco, PhD, said during a July 31 conference call.
You may also be interested in...
Bayer Beefs Up Biologics Pipeline With Direvo Biotech Buy
Separate spin-out transaction establishes Direvo’s industrial biotech business as an independent entity.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011